Clinical trial · Observational
Detection of Aggressive Breast Tumors Using Tc-99m-NC100692
Improved Sensitivity for the Detection of Aggressive Breast Tumors Using 99mTc-NC100692 and a Dual-headed Small Field of View CZT Gamma Camera.
NCT00888589CI-TRIAL-00014119completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare two types of radioactive drugs to see if they provide the same or different information about any disease that may be present in the participants breast.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evidence of disease confirmed by surgery, or benign disease confirmed by biopsy
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Have a lesion on mammogram, ultrasound or breast MRI that measured \< 15 mm in diameter, is considered suggestive or highly suggestive of malignancy according to the Breast Imaging Reporting and Data System Atlas criteria (BIRADS 4b, 4c or 5), and is scheduled for biopsy (needle biopsy and/or surgical biopsy). OR * Have a lesion on mammogram, ultrasound or breast MRI that measured \> 15 mm in diameter, is known to be malignant and is scheduled for surgery. * Patient age \> 18 years of age. * Have a negative pregnancy test on the first day of the study, or must be postmenopausal or surgically sterilized. Exclusion Criteria: * Patients will be excluded if they have a small lesion (\< 15 mm) and have undergone prior needle biopsy of the lesion (such biopsy may effectively remove all or part of the lesion and angiogenesis associated with wound healing might confound imaging results with 99mTc-NC100692). * Patient's pregnancy is not negative on the first day of the study, or the patient is unable to complete the pregnancy test * Patient is unable to sit on a chair for 40 minutes
References
Publications (1)
- DERIVEDO'Connor MK, Morrow MMB, Hunt KN, Boughey JC, Wahner-Roedler DL, Conners AL, Rhodes DJ, Hruska CB. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. EJNMMI Res. 2017 Dec;7(1):5. doi: 10.1186/s13550-017-0255-6. Epub 2017 Jan 14. PMID 28091980